

LETTER

DNMT3A reads and connects histone H3K36me2 to DNA methylation

Dear Editor,

DNA methylation at the 5-position of cytosine (5mC) is a crucial epigenetic mark in regulating biological processes including gene silencing, gene imprinting, and X chromosome inactivation (Jaenisch and Bird, 2003; Smith and Meissner, 2013). Human genome encodes three DNA methyltransferases, DNMT1, DNMT3A and DNMT3B to catalyze 5mC. Although not tightly restricted, DNMT1 is thought to maintain the established pattern of 5mC throughout DNA replication, while DNMT3A and DNMT3B are largely responsible for the de novo establishment of 5mC. It has long been questioned how de novo DNA 5mC patterns are established in different genomic regions and whether histone modifications crosstalk to the process. Until recently, it was reported that through recognition of histone H3K36me3 mark, DNMT3B plays a dominant role in mediating DNA 5mC in the genic region undergoing active transcription (Baubec et al., 2015; Neri et al., 2017). However, 5mC occurs at both intergenic and genic regions, while H3K36me3 is largely absent in the intergenic regions, indicating that the intergenic 5mC may be mediated through different mechanisms.

Although H3K36me3 is involved in the DNMT3B mediated DNA 5mC in the genic regions (Baubec et al., 2015; Neri et al., 2017), we found that SETD2 loss in HEK293T cells did not cause reduction of global 5mC level, which was actually moderately increased by around 20% (Fig. S1A, left and middle), indicating alternative mechanism in directing DNA 5mC by histone modifications might exist. Unexpectedly, in the SETD2 KO HEK293T cells, we also observed an obvious increase of H3K36me2 (Fig. S1A, right). Such gain of H3K36me2 and increase of 5mC in the SETD2 KO HEK293T cells raised an interesting possibility of H3K36me2 in regulating DNA 5mC. To explore this possibility, we first compared the distribution patterns of 5mC with various well-characterized histone modifications, including H3K36me2, using public available datasets (Figs. 1A and S1B). Consistently, we observed a strong correlation between H3K36me2 and 5mC ($R = 0.85$) in MDA-MB-231 cells, which is even higher than that between H3K36me3 and 5mC ($R = 0.63$, Fig. 1A). The correlations between 5mC and H3K36me3 in 2 other cell lines are also around the same

range ($R = 0.64$ – 0.66 , Fig. S1B). Importantly, further genomic distribution analyses revealed that the similarity between 5mC and H3K36me3 is restricted to genic regions as reported previously (Baubec et al., 2015; Morselli et al., 2015), while that between 5mC and H3K36me2 is mainly in the intergenic regions and the immediate upstream to promoter regions in MDA-MB-231 cells (Fig. 1B, compare the blue and orange lines). Using the same approach, we found that H3K9me3 and H3K27me3 are poorly correlated with 5mC in MDA-MB-231 (Fig. S1C), indicating that the strong correlation between 5mC and H3K36me2 is rather specific.

Among the three DNA methyltransferases, both DNMT3A and DNMT3B possess a PWWP domain. As PWWP domain was reported to be capable in recognizing H3K36me2 or H3K36me3 (Sankaran et al., 2016), we hypothesized that the PWWP domain of DNMT3A may be able to read H3K36me2 and play a recruitment function for DNMT3A. Consistent with this idea, in vitro pull-down assay readily identified a specific interaction between H3K36me2 and the PWWP of DNMT3A (Fig. 1C). Interestingly, we found that the interaction was substantially stronger than that of H3K36me3 (Fig. 1C), and such preference was not affected by the sequence variation at the 31 position of the histone variants H3.1/2 and H3.3, despite the interactions with H3.3 peptides were generally weaker (Fig. 1C). Consistently, recombinant full length DNMT3A2 (isoform 2) purified from *E. coli* also preferentially binds H3K36me2 compared to H3K36me3 (Fig. 1C).

Various crosstalk mechanisms between histone modifications and 5mC have been documented, and it was known that the histone H3K4 methylations, especially H3K4me2/3, could strongly repress DNMT3A activity through ADD domain providing a mechanism to protect active promoters and enhancers from DNA 5mC methylation (Zhang et al., 2010; Li et al., 2011; Guo et al., 2015). We therefore wondered whether H3K36me2 binding by the PWWP domain could also affect the enzymatic activity of DNMT3A. To address this, we carried out in vitro methyltransferase assay using recombinant full length DNMT3A2 protein purified from insect cells and DNA substrate by spiking in H3K36me2 modified as well as several control histone peptides (Fig. 1D). In support of our hypothesis, we found that while H3K36me1 and H3K36me3 peptides only had minimal




Figure 1. Genome-wide correlation between DNA 5mC and H3K36me2 and DNMT3A preferentially binds and is activated by H3K36me2. (A) Scatterplots showing genome-wide correlation between H3K36me2 and 5mC (left), and H3K36me3 and 5mC (right) in MDA-MB-231 cell. The number of reads was counted in nonoverlapping 100-kb bins spanning the human genome. The correlation coefficient was calculated with Pearson correlation. (B) Aggregation plot showing the distribution patterns of 5mC, H3K36me2 and H3K36me3 in the indicated genomic regions. (C) Schema of DNMT3A2 domain architecture and biotinylated peptide pull-down assay of DNMT3A2 FL and PWWP domain with the indicated histone H3.1K36 and H3.3K36 peptides. (D) *In vitro* DNA methylation assay testing the stimulation of DNMT3A activity with the indicated histone peptides (H3.1 22-44aa) (***P* value < 0.01) (left, radioactivity), and at different concentrations (right, Michaelis-Menten graph analyses, MBD2b based).

effects on DNMT3A activity, H3K36me2 peptides could significantly activate DNMT3A at a concentration as low as 3.2 $\mu\text{mol/L}$, using two independent, radioactivity and MBD domain-based, methylation detection methods (Fig. 1D).

In order to understand the biological impact of the axis of histone H3K36me2 and DNA 5mC, we turned to a well-characterized multiple myeloma model, KMS11 and KMS11^{TKO}. KMS11 contains a chromosomal translocation event, T(4;14), which leads to massive overexpression of NSD2 and genome-wide gain of H3K36me2 (Kuo et al., 2011). While in KMS11^{TKO}, the translocation event was specifically knocked out, resulting in monoallelic expression of NSD2 and close to normal level of H3K36me2 (Fig. 2A). Consistent with our *in vitro* results, both dot blot and quantitative HPLC analyses found that the extracted KMS11 genomic DNA contains around 30% more DNA 5mC compared to that of KMS11^{TKO}, which is a significant alteration of global 5mC level (Fig. 2B).

Through MeDIP-seq and H3K36me2 ChIP-seq approaches in KMS11 and KMS11^{TKO} cells, we again observed strong correlations between H3K36me2 and DNA methylation genome-wide (Fig. 2C). Interestingly, the correlation is significantly higher in KMS11^{TKO} compared to KMS11 (Fig. 2C), indicating the abnormal hyper H3K36me2 significantly impaired proper 5mC establishment in KMS11. Close examination of mapped H3K36me2 and 5mC genome tracks found that the both marks are more dispersedly distributed in KMS11 genome due to genome-wide hyper H3K36me2 (Fig. 2D). While in KMS11^{TKO} cells, we found that most intergenic H3K36me2 signals were lost as the result of loss of NSD2 overexpression, and the remaining H3K36me2 signals were generally retained in the genic and surrounding regions, exemplified by *ARHGAP44* and *COX10* in Fig. 2D. Consistent with our hypothesis, we also observed significant reduction of the intergenic 5mC in KMS11^{TKO} (Fig. 2D, shadowed regions). Notably, genic 5mC signals were largely




Figure 2. Hyper DNA 5mC in KMS11 is dependent on NSD2 overexpression and is specific required for KMS11 growth. (A) Western blot showing the expression level of NSD2 and H3K36me2 in the KMS11, KMS11^{TKO} and KMS11^{TKO}+NSD2 (with NSD2 expression using a rescuing construct) cells. Ponceau staining of the histone region as loading control. (B) Global DNA 5mC analyses of the KMS11, KMS11^{TKO} and KMS11^{TKO}+NSD2 cells using dot blot (left) and HPLC (right) approaches. ** $P < 0.01$, * $P < 0.05$, t-test. (C) Scatterplots showing the correlation of H3K36me2 and 5mC in KMS11 and KMS11^{TKO} cells. (D) UCSC track snapshot showing the distribution patterns of H3K36me2 and 5mC in the indicated genomic region in KMS11 and KMS11^{TKO} cells. (E) Pie chart analyses of the genomic distribution of H3K36me2 (top) and 5mC (bottom) peaks specific to KMS11 or KMS11^{TKO} cells. (F) Cell growth analyses of KMS11 and KMS11^{TKO} cells under the treatment of 5-Aza at the indicated concentrations for 4 days (** $P < 0.01$, t-test).

retained and in certain cases, such as *COX10*, even increased in KMS11^{TKO} (Fig. 2D), likely due to the effect of relatively enriched focal H3K36me2. We also noticed that, in KMS11^{TKO}, not all genic 5mC signals matched H3K36me2 patterns (for examples, *HS3ST3A1* and *HS3ST3B1* in Fig. 2D), and we speculated that H3K36me3 might play a recruitment role in these regions. Consistent with the observations in Fig. 2D, the genomic distributions of KMS11-specific H3K36me2 and 5mC peaks are similar as average genome proportion (genic 45.3% and intergenic 54.7%), while KMS11^{TKO}-specific peaks are more enriched in genic regions (Fig. 2E).

To further explore the functional importance on gene expression by the H3K36me2 and DNA 5mC axis, we carried out RNA-seq analyses in KMS11 and KMS11^{TKO} cells (Fig. S2A). As revealed by other studies (Kuo et al., 2011), we identified hundreds of differentially expressed genes (DEGs). Among these DEGs, we found that the up-regulated genes in KMS11 are significantly enriched for pathways in cancer (Fig. S2B), and the altered expression of several oncogenes in myeloma, such as *HSPG2*, *TREML2* and *NCAM1* were validated by RT-qPCR (Fig. S2C). We also found that the upregulated genes in KMS11 showed higher upstream DNA 5mC which tended to be lost in KMS11^{TKO}, compared to the downregulated genes (Fig. S2D, left). While the 5mC levels of the CpG islands at the transcription start sites (TSSs) of the up- and down-regulated genes were generally low and similar, although statistically significant (Fig. S2D, right). This observation raises an intriguing possibility of the upstream hyper 5mC in KMS11 being functionally involved in the downstream gene transcription, which certainly needs future investigation.

As NSD2 overexpression was demonstrated as the driver mutation for multiple myeloma bearing T(4;14) translocation (Keats et al., 2003; Santra et al., 2003; Kuo et al., 2011), we therefore speculated that the gain of 5mC as the consequence of NSD2 overexpression may also functionally involved in the tumorigenic processes. Supporting this idea, we found that the application of DNA methylation inhibitor, 5-Aza, effectively suppressed the proliferation of KMS11 cells at 0.25 μ mol/L in 4 days (Fig. 2F). While under same condition, even at 1 μ mol/L concentration, 5-Aza showed no effect on the proliferation of KMS11^{TKO}, indicating that the global hypermethylation of 5mC is required for cancerous growth driven by NSD2 overexpression in KMS11.

Our findings revealed a previously under-appreciated function of H3K36me2 in regulating DNMT3A mediated DNA 5mC. Although partially overlapped in genic regions with H3K36me3, H3K36me2 also demarcates many intergenic regions. Together with the fact that H3K36me3 directs genic DNA 5mC methylation through DNMT3B (Baubec et al., 2015), H3K36 methylations play critical role in guiding

DNMT3A and DNMT3B to keep the proper level of DNA 5mC methylation genome-wide. Interestingly, both H3K36me2 and H3K36me3 are absent in the promoter regions, consistently with and perhaps also mechanistically contribute to the 5mC hypomethylation at the active promoters. Furthermore, as NSD family members frequently undergo gain-of-function mutations in MM, AML, lung and breast cancers (Rosati et al., 2002; Wang et al., 2007; Oyer et al., 2014), our findings also support therapeutic opportunities for DNA methylation inhibitors in treating these tumors.

FOOTNOTES

We thank Dr. Yanhui Xu for sharing DNMT3A related reagents. This project was supported by the National Key Research and Development program of China (2016YFA0101800 to F.L., 2018YFC1005004 to F.W., 2018YFA0108700 and 2016YFC1000500), the Shanghai Municipal Science and Technology Major Project (2017SHZDZX01), the National Natural Science Foundation of China (81272295 to F.W., 81773014 to F.L. and 31900469 to W.X.).

Fei Lan is a consultant of Active Motif Inc. and shareholder of Constellation Pharmaceuticals. Wenqi Xu, Jiahui Li, Bowen Rong, Bin Zhao, Mei Wang, Ruofei Dai, Qilong Chen, Hang Liu, Zhongkai Gu, Shuxian Liu, Rui Guo, Hongjie Shen and Feizhen Wu declare that they have no conflict of interest.

This article does not contain any studies with human or animal subjects performed by the any of the authors.

Wenqi Xu¹, Jiahui Li¹, Bowen Rong¹, Bin Zhao¹, Mei Wang², Ruofei Dai¹, Qilong Chen³, Hang Liu¹, Zhongkai Gu¹, Shuxian Liu¹, Rui Guo¹, Hongjie Shen¹ , Feizhen Wu¹ , Fei Lan¹ 

¹ Key Laboratory of Birth Defects, Children's Hospital, Fudan University, and Key Laboratory of Epigenetics, Institutes of Biomedical Sciences, Fudan University, Shanghai 201102, China

² Department of Geriatrics, Shanghai General Hospital, Shanghai 201103, China

³ Research Center for Chinese Traditional Medicine Complexity System, Shanghai University of Chinese Traditional Medicine, Shanghai 201203, China

✉ Correspondence: hongjieshen@fudan.edu.cn (H. Shen), wufz@fudan.edu.cn (F. Wu), fei_lan@fudan.edu.cn (F. Lan)

OPEN ACCESS

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

REFERENCES

- Baubec T, Colombo DF, Wirbelauer C, Schmidt J, Burger L, Krebs AR, Akalin A, Schubeler D (2015) Genomic profiling of DNA methyltransferases reveals a role for DNMT3B in genic methylation. *Nature* 520:243–247
- Guo X, Wang L, Li J, Ding Z, Xiao J, Yin X, He S, Shi P, Dong L, Li G et al (2015) Structural insight into autoinhibition and histone H3-induced activation of DNMT3A. *Nature* 517:640–644
- Jaenisch R, Bird A (2003) Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. *Nat Genet* 33(Suppl):245–254
- Keats JJ, Reiman T, Maxwell CA, Taylor BJ, Larratt LM, Mant MJ, Belch AR, Pilarski LM (2003) In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. *Blood* 101:1520–1529
- Kuo AJ, Cheung P, Chen K, Zee BM, Kioi M, Larring J, Xi Y, Park BH, Shi X, Garcia BA et al (2011) NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. *Mol Cell* 44:609–620
- Li BZ, Huang Z, Cui QY, Song XH, Du L, Jeltsch A, Chen P, Li G, Li E, Xu GL (2011) Histone tails regulate DNA methylation by allosterically activating de novo methyltransferase. *Cell Res* 21:1172–1181
- Morselli M, Pastor WA, Montanini B, Nee K, Ferrari R, Fu K, Bonora G, Rubbi L, Clark AT, Ottonello S et al (2015) In vivo targeting of de novo DNA methylation by histone modifications in yeast and mouse. *Elife* 4:e6205
- Neri F, Rapelli S, Krepelova A, Incarnato D, Parlato C, Basile G, Maldotti M, Anselmi F, Oliviero S (2017) Intragenic DNA methylation prevents spurious transcription initiation. *Nature* 543:72–77
- Oyer JA, Huang X, Zheng Y, Shim J, Ezponda T, Carpenter Z, Allegretta M, Okot-Kotber CI, Patel JP, Melnick A et al (2014) Point mutation E1099K in MMSET/NSD2 enhances its methyltransferase activity and leads to altered global chromatin methylation in lymphoid malignancies. *Leukemia* 28:198–201
- Rosati R, La Starza R, Veronese A, Aventin A, Schwienbacher C, Vallespi T, Negrini M, Martelli MF, Mecucci C (2002) NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15). *Blood* 99:3857–3860
- Sankaran SM, Wilkinson AW, Elias JE, Gozani O (2016) A PWWP domain of histone-lysine N-methyltransferase NSD2 binds to dimethylated Lys-36 of histone H3 and regulates NSD2 function at chromatin. *J Biol Chem* 291:8465–8474
- Santra M, Zhan F, Tian E, Barlogie B, Shaughnessy JJ (2003) A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. *Blood* 101:2374–2376
- Smith ZD, Meissner A (2013) DNA methylation: roles in mammalian development. *Nat Rev Genet* 14:204–220
- Wang GG, Cai L, Pasillas MP, Kamps MP (2007) NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. *Nat Cell Biol* 9:804–812
- Zhang Y, Jurkowska R, Soeroes S, Rajavelu A, Dhayalan A, Bock I, Rathert P, Brandt O, Reinhardt R, Fischle W et al (2010) Chromatin methylation activity of Dnmt3a and Dnmt3a/3L is guided by interaction of the ADD domain with the histone H3 tail. *Nucleic Acids Res* 38:4246–4253

Wenqi Xu, Jiahui Li and Bowen Rong contributed equally to this work.

Electronic supplementary material The online version of this article (<https://doi.org/10.1007/s13238-019-00672-y>) contains supplementary material, which is available to authorized users.